Tyrosine Kinase Inhibition (TKI) is well established in treatment of Renal Cell Carcinoma (RCC), however all patients do not respond to this therapy. Farcast's TruTumor platform was used for evaluating response in RCC patients with Sunitinib and Nivolumab. While most tumors in the cohort showed a response to TKI therapy, some who failed showed the potential of an early response to anti-PD1 therapy. To find out more, download Farcast's poster, published at AACR 2023 in Orlando. 

Interested in learning about Farcast's versatile TruTumor platform, contact us at biopharma@farcastbio.com